Citations

Clear

365 citation(s) found for "Richardson, PG".

Building trauma-informed physical therapists: a mixed-methods evaluation of a multimodal training module in hybrid DPT education
Parr, Rebecca E. , Richardson, Michael V., Anderson, Kristen, Anderson, Kristen

Mayo Clinic

Physiotherapy Theory and Practice | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1080/09593985.2026.2730589 | PMID 42708499 Get It

Continued concomitant antibiotic or immunosuppression therapies reduce the risk of pouchitis among patients with ileal pouch-anal anastomosis and primary sclerosing cholangitis
Haydek, John P. , Santiago, Priscila , Powers, Joseph Carter , Ruplall, Latchmin, Richardson, Hoang Anh, Causey, Erin, Elhawary, Mohamed, Karl, Taylor , Tfayli, Rami , Hashash, Jana G. , Qazi, Taha , Horst, Sara , Long, Millie D. , Raffals, Laura E. , Chang, Shannon , Horst, Sara , Scott, Frank I , Long, Millie D , Raffals, Laura , Barnes, Edward L , Hashash, Jana G , Haydek, John , Karl, Taylor A. , Chang, Sam S. , Scott, Frank I. , Barnes, Edward L.

Mayo Clinic

Crohn’s & Colitis 360 | August 3, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag091 | PMID 42598726 Get It

Abstract Background Complications such as intermittent pouchitis (IP) and chronic inflammatory disorders of the pouch (CP) are common after ileal pouch-anal anastomosis (IPAA), particularly among patients with both ulcerative colitis and primary sclerosing cholangitis (PSC). There are no standardized approaches for prophylaxis against these complications for patients with PSC undergoing IPAA. We compared outcomes among patients with PSC and IPAA who received antibiotic or immunosuppressive therapies to those who did not. Methods We designed a retrospective cohort study that included patients with ulcerative colitis and PSC from 7 tertiary care centers that underwent IPAA between 1994 and 2023. Patients were categorized on whether they received medications following IPAA that may provide primary prophylactic benefit, such as antibiotics, probiotics, immunomodulators, or biologic medications; and the proportion of patients developing IP and CP was evaluated. Results A total of 172 patients were included in the cohort, and 13 (7.6%) patients received antibiotics or immunosuppressant medications. Antibiotics and probiotics were the most common therapy (5 patients, 2.9%), followed by biologics, small-molecule inhibitors, immunomodulators, or mesalamine (all 1 patient, 0.6%). Compared to patients not receiving antibiotics or immunosuppression, patients receiving antibiotics or immunosuppression were significantly less likely to develop IP (69.2% vs 91.2%; P = .03; odds ratio 0.22; 95% CI, 0.06-0.80) and CP (23.1% vs 56.0%, P = 0.04; OR 0.24, 95% CI, 0.06-0.89). Conclusions In this retrospective cohort of patients with ulcerative colitis and PSC undergoing IPAA, usage of concomitant antibiotics or immunosuppression was low. However, use of concomitant antibiotics or immunosuppression may decrease the burden of inflammatory conditions of the pouch in these high-risk patients.
Intraoperative EndoFLIP TM Driven Paraesophageal Hernia Repair Without Fundoplication: Heresy or Good Practice?
Mukharjee, Sourodip , Heard, Jessica, Ibrahim, Mira, Karumuri, Jashwanth, Osman, H., Jeyarajah, D. Rohan , Heard, Jessica C. , Karumuri, Jashwanth , Osman, Houssam G.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/26345161261473024 Get It

Background: The study aims to evaluate the postoperative outcomes of hiatal hernia repair with cruroplasty alone compared to the addition of fundoplication. We theorize that previously reported inferiority with crural-only repairs resulted from a lack of real-time feedback regarding the effectiveness of the repair. EndoFLIP TM allows for intraoperative assessment of the gastroesophageal junction. We predict equivalent postoperative outcomes will be achieved between hiatal hernia repairs performed by cruroplasty alone and with fundoplication when the final distensibility index (DI) is similar. Methods: This retrospective cohort review includes patients who underwent hiatal hernia repair with intraoperative EndoFLIP TM between 2020 and 2022. Propensity score-matching was utilized to identify cruroplasty alone and fundoplication patients with a final DI within 0.5 mm 2 /mmHg of one another. Postoperative development of dysphagia, reflux, or hernia recurrence were primary outcomes of interest. Results: Forty-two patients were included in the analysis. While the cruroplasty-alone cohort had an increased age at the time of surgery, 50% more redo repairs, and a slightly higher BMI, there were no significant preoperative or intraoperative differences between groups. Overall, the median duration of follow-up was 111 (IQR 213) days. During that time, there were no differences in the development of postoperative reflux or dysphagia between cohorts ( P = .228 and P = .451, respectively). Kaplan-Meier curve analysis did not demonstrate a significant difference in time-to-event for either outcome. There were 3 radiographic recurrences, with 2 occurring after fundoplication ( P = .000). Conclusions: This is the first study to utilize intraoperative EndoFLIP TM to determine the need for fundoplication during hiatal hernia repair. The results demonstrate no additional short-term benefit from fundoplication performance. These findings argue against routine fundoplication when an acceptable DI can be achieved after cruroplasty. Further research is needed to validate these results.
Evaluating MAPT p.A152T as a risk factor for the 3R tauopathy Pick’s disease
Tamvaka, Nicole , Scotton, William J. , Lilley, Meredith T. , Shoai, Maryam , Gavrielatos, Marios , HECKMAN, M, Roemer, Shanu F, Baker, Matthew C, Rademakers, Rosa, Hardy, John , Cook, Casey , Lashley, Tammaryn , Jaunmuktane, Zane, Mok, Kin, Revesz, Tamas, Christopher, Elizabeth, DeTure, Michael, Koga, Shunsuke, Graff-Radford, Neill R, Boeve, Bradley F, Josephs, Keith A. , Petersen, Ronald C, Whitwell, Jennifer , Duara, Ranjan, Lyons, Kelly E, Miller, Bruce, Schlereth, Athena, Spina, Salvatore, Irwin, David J, Wolk, David A, Suh, EunRan, Deerlin, Vivianna M Van, Lee, Edward B, Frosch, Matthew P. , Molina-Porcel, Laura, Aldecoa, Iban, Balasa, Mircea, Borrego-Ecija, Sergi, Sanchez-Valle, Raquel, Gascón‐Bayarri, Jordi , Sanz-Cartagena, Pilar , Huélamo, Rosa Maria de Eugenio, Gefen, Tamar, Castellani, Rudolph J, Rogalskı, Emily , Weıntraub, Sandra , Bieniek, Kevin F, Zhu, Xiongwei, Redding-Ochoa, Javier, Troncoso, Juan C. , Ghetti, Bernardino, Newell, Kathy L. , Jacobsen, Max, Roncaroli, Federico, Jones, Matthew, Richardson, Anna, Snowden, Julie, Allinson, Kieren, Beach, Thomas G, Teich, Andrew F, Flowers, Xena, Heaps, Allison C, Leskinen, Sandra , Keith, Julia , Masellis, Mario, King, Andrew, Sarraj, Safa-Al, Hodges, John R. , Gearing, Marla , Roeber, Sigrun, Attems, Johannes, Boluda, Susana , Seilhean, Danielle, Ber, Isabelle Le, Turbant-Leclere, Sabrina, Mackenzie, Ian R. , Sieben, Anne, Cras, Patrick , Vil, Bart B De, Deyn, P P De, Keene, C Dirk, Latimer, Caitlin S. , Schantz, Aimee, Bird, Thomas D, Haroutunian, Vahram, Purohit, Dushyant, Rissman, Robert, Cykowski, Matthew D. , Wang, Shih-Hsiu J, Ervin, John F. , Nennesmo, Inger , Nagra, Rashed M. , Riehl, James, Kovacs, Gabor G, Neumann, Manuela, Ang, Lee-Cyn, Cunha, Cristina, Blauwendraat, Cornelis , Nalls, Mike A., Singleton, Andrew B, Perrin, Richard J. , Chaffee, Anne M, Scotton, William , Murray, Melissa E , Dickson, Dennis W , Ross, Owen A , Hardy, John , Shoai, Maryam , Lashley, Tammaryn , Heckman, Michael G. , Soto‐Beasley, Alexandra I. , Roemer, Shanu F. , Rademakers, Rosa , Murray, Melissa E. , Dickson, Dennis W. , Rohrer, Jonathan D. , Ross, Owen A. , Valentino, Rebecca R. , Macpherson, Hannah L. , Warner, Thomas T. , Jaunmuktane, Zane , Martínez-Carrasco, Alejandro , Revesz, Tamas, DeTure, Michael , Koga, Shunsuke , Graff‐Radford, Neill R. , Boeve, Bradley F. , Petersen, Ronald C. , Duara, Ranjan, Pahwa, Rajesh , Grinberg, Lea T. , Seeley, William W. , Miller, Bruce L , Spina, Salvatore , Suh, EunRan , Deerlin, Vivianna M. Van , Connors, Theresa R. , Oakley, Derek H. , Molina‐Porcel, Laura , Aldecoa, Ibán , Balasa, Mircea , Borrego‐Écija, Sergi , Sánchez‐Valle, Raquel , Piñol‐Ripoll, Gerard , Gelpí, Ellen , Gefen, Tamar , Castellani, Rudolph J. , Flanagan, Margaret E. , Schneider, Julie A. , Bieniek, Kevin F. , Redding‐Ochoa, Javier , Chang, Koping , Prokop, Stefan , Ghetti, Bernardino, Robinson, Andrew , Roncaroli, Federico , Kobylecki, Christopher , Richardson, Anna, Rowe, James B. , Quaegebeur, Annelies , Allinson, Kieren Simon James, Beach, Thomas G. , Serrano, Geidy E. , Teich, Andrew F. , Black, Sandra E. , Masellis, Mario, Troakes, Claire , Halliday, Glenda M. , Kril, Jillian J. , Kwok, John B. , Piguet, Olivier , Morris, Christopher M. , Thomas, Alan , White, Charles L. , Evers, Bret M. , Mechawar, Naguib , Seilhean, Danielle , Ber, Isabelle Le , Leclère-Turbant, Sabrina, Vil, Bart De , Deyn, Peter Paul De , Keene, C Dirk, Haroutunian, Vahram , Purohit, Dushyant P. , Walker, Jamie M. , Rissman, Robert A. , McLean, Catriona , Graff, Caroline , Riehl, James R. , Giaccone, Giorgio , Neumann, Manuela , Finger, Elizabeth C. , Carvalho, Agostinho , Morris, Huw R. , Singleton, Andrew B, Vitale, Dan , Chaffee, Ann, Wszołek, Zbigniew K.

Mayo Clinic

Brain Communications | July 9, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag266 | PMID 42553595 Get It

Abstract Genetic studies have significantly advanced our understanding of tauopathies, yet the genetic aetiology of Pick’s disease, a rare 3-Repeat tauopathy, remains unclear. The MAPT p.A152T variant has been identified as a risk factor for Alzheimer’s disease and progressive supranuclear palsy, but its role in Pick’s disease is unknown. In this study, we examined the prevalence of MAPT p.A152T in the largest series of neuropathologically confirmed Pick’s disease cases to date (n = 401). Through genotyping, we identified a single mutation carrier in the Pick’s disease cohort (minor allele frequency = 0.12%). We previously reported MAPT p.A152T at a 0.20% frequency in healthy controls (n = 2456), suggesting that it does not associate with 3-Repeat tauopathy risk. To further investigate the effect of the variant on MAPT transcript expression, we used bulk RNA sequencing in Alzheimer’s disease and progressive supranuclear palsy A152T mutation carriers. We did not detect significant differences in 4-Repeat tau levels, though preliminary trends may indicate more nuanced effects that need to be examined with long-read sequencing in a larger series. Overall, our study suggests that MAPT p.A152T does not increase Pick’s disease risk and may instead be linked to 4-Repeat or mixed tau pathologies, warranting further functional investigation.
Responsive stimulation of the thalamus for idiopathic generalized epilepsy: Results of the randomized controlled NAUTILUS trial through 18 months
Uysal, Utku, Landazuri, Patrick , Patra, Sanjay, Crudele, Angela, Englot, Dario, Gavvala, Jay R., Tandon, Nitin, Pati, Sandipan , Kaye, Lesley , Ojemann, Steven, Barnett, Daniel, Neimat, Joseph, Palade, Adriana , Rahimpour, Shervin, Arain, Amir A., Cash, Sydney S., Salanova, Vicenta , Urban, Alexandra, Welch, W. Pete, Gonzalez-Martinez, Jorge A., Spencer, David, Rivera‐Cruz, Angélica , Dugan, Patricia, Fajardo, Marytery , Lallas, Matt, Odom, Nicole, Roland, Jarod L. , Willie, Jon T., Sheth, Sameer A., Skidmore, Christopher T., Drees, Cornelia , Parker, Jonathon, Szaflarski, Jerzy P. , Johnson, Lise, Norman, Jacob F. , Wingeier, Brett, Group, Nautilus Study, Group, Nautilus Study, Englot, Dario J. , Englot, Dario J , Richardson, Robert Mark , Van Gompel, Jamie J , Starnes, Keith , Ernst, Lia D , Amin, Ushtar , Roland, Jarod L , Goldman, Alica M , Wu, Chengyuan , Drees, Cornelia , Ganguly, Taneeta Mindy , Szaflarski, Jerzy , Johnson, Lise , Norman, Jacob F , Landazuri, Patrick , Burdette, David E. , Patra, Sanjay , Gavvala, Jay R. , Tandon, Nitin , Pati, Sandipan Bankim Behari , Kaye, Lesley C , Ojemann, Steven , Neimat, Joseph S. , Rahimpour, Shervin , Arain, Amir M. , Cash, Sydney S. , Urban, Alexandra , González-Martínez, Jorge , Gompel, Jamie J. Van , Ernst, Lia , Dugan, Patricia , Jobst, Barbara C. , Willie, Jon T , Sheth, Sameer A. , Goldman, Alica M. , Skidmore, Christopher , Wu, Chengyuan , Parker, Jonathon J. , Ganguly, Taneeta M. , Ghatan, Saadi , Wingeier, Brett , Seale, Cairn G. , Morrell, Martha J.

Mayo Clinic

Epilepsia | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70321 | PMID 42233958 Get It

Abstract Objective This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive therapy for drug‐resistant idiopathic generalized epilepsy (IGE) with generalized tonic–clonic seizures (GTCSs). Methods NAUTILUS is a prospective, multicenter, single‐blind, randomized sham‐controlled pivotal trial. Patients were ≥12 years of age with drug‐resistant IGE and ≥2 GTCSs over a 3‐month baseline. Bilateral depth leads were targeted to the centromedian thalamus. One month later, patients were randomized to Active (responsive stimulation, n = 44) or Sham (no stimulation, n = 43). The effectiveness evaluation period (EEP) began 3 months postimplant through 1 year. After a second GTCS in the EEP, patients transitioned to open‐label active stimulation. The primary safety endpoint was the serious adverse device‐related event (SADE) rate at 84 days postimplant. The primary effectiveness endpoint was time‐to‐second‐GTCS during the EEP. Additional endpoints included median percent change in days with any generalized seizure, GTCS frequency, and responder rate (RR). Results Eighty‐seven patients were implanted across 23 US centers. The SADE rate was significantly below the performance goal (6.9%, p < .0001), with no adverse effects on cognition, mood, or sleep. The prespecified primary effectiveness endpoint was not significant. However, a post hoc mixed‐effects model considering all EEP days demonstrated greater GTCS reduction in the originally randomized Active group (61%) compared to patients originally randomized to Sham (49%, p = .030). Eighteen‐month outcomes included 76.8% median GTCS reduction, 62.5% RR, 40% GTCS‐free at that timepoint, and 77.8% median reduction in days with any generalized seizure. More than 90% of patients and 86% of physicians reported improvement on Global Impression of Change scales. Significance NAUTILUS is the first randomized controlled neuromodulation trial in IGE. Responsive thalamic stimulation provided a clinically meaningful and durable reduction in seizures with an acceptable safety profile, offering a much‐needed option for drug‐resistant IGE.
Integrating enriched case data from national laboratory testing with population-based case-control analyses: a novel statistical likelihood-ratio methodology for PS4 applied to 325,345 breast cancer cases and 671,006 controls
Garrett, Alice, Couch, Fergus, Richardson, Marcy E, Pesaran, Tina, Pethick, Joanna , Lavelle, Katrina , McRonald, Fiona, Vernon, Sally , Torr, Bethany , Aungraheeta, Riyaad, Callaway, Alison , Robinson, Rachel, Field, Joanne, Frugtniet, Bethan, Palmer-Smith, Sheila, Pagan, Judith, McDevitt, Trudi , Snape, Katie, Hanson, Helen, McVeigh, Terri, Loveday, Chey , Jones, Michael, Hardy, S , Turnbull, Clare, CanVIG-UK, Turnbull, Clare , Allen, Sophie , Rowlands, Charlie F , Garrett, Alice , Couch, Fergus J. , Richardson, M. E., Pesaran, Tina , McRonald, Fiona E. , Loong, Lucy , Durkie, Miranda , Burghel, George J. , Robinson, Rachel , Frugtniet, Bethan A., Palmer-Smith, Sheila, Grant, Jonathan , Snape, Katie , Hanson, Helen , McVeigh, Terri Patricia , CanVIG-UK

Mayo Clinic

No container title available | May 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26353095 | PMID 42180364 Get It

Abstract Background For many evidence criteria within v3.0 of the ACMG/AMP guidelines, methodologies have been developed to empower their use outside the stipulated evidence strengths. However, no such methodology has been established for case-control data (PS4). With the release of large-scale unselected case-control datasets and expansion of nationally-collected laboratory datasets enriched for pathogenic variant carriers, there is potential to combine datasets across ascertainment contexts in a more quantitative manner using novel likelihood ratio tools. Methods Using our published PS4-LR-Calculator, we calculated a combined log likelihood ratio (PS4-LLR) across five datasets (three unselected, and two enriched), and estimated enrichment of pathogenic variants in clinically-ascertained laboratory data using truncating variant prevalence. Results Data were combined for 10,817 missense variants from 325,345 female breast cancer patients and 671,006 controls of Western European ancestry for five breast cancer susceptibility genes ( BRCA1, BRCA2, PALB2, ATM, CHEK2 ). A combined LLR was produced for 4,690 missense variants; 927 variants received evidence towards pathogenicity (LLR≥ 1), and 3,242 received evidence towards benignity (LLR≤ -1). Conclusion This flexible, variant-level methodology combines nationally-collected ‘enriched’ datasets with unselected case-control cohorts, expanding the available information for case-control analysis, boosting power, enabling exploration of atypical penetrance and empowering variant classification.
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal women
Cui, Jinghan, Hankinson, Susan E. , Santen, Richard J. , Boutot, Maegan E., Budd, Jeffrey R. , Dowsett, Mitch, Goetz, Matthew P, Guranich, Catherine, Houghton, Serena, Ingle, J , Jones, Micheal E., Rinaldi, Sabina , Rosner, Bernard, Vesper, Hubert W. , Eliassen, A Heather, Swerdlow, Anthony J, Vachon, Celine M. , Richardson, Harriet , Qian, Jing , Jones, Michael E. , Rinaldi, Sabina , Singh, Ravinder J , Vachon, Celine M. , Qian, Jing , Hankinson, Susan E. , Jones, Michael E , Matsumoto, Alvin M. , Dowsett, Mitch , Houghton, Serena C. , Ingle, James N. , Rosner, Bernard A., Schoemaker, Minouk J. , Milne, Roger L. , Swerdlow, Anthony J

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1210/clinem/dgag188 | PMID 42120349 Get It

Abstract Context Prior reports of plasma estradiol concentrations and their reference ranges in postmenopausal women identified marked variation, in part due to assay method and body mass index (BMI). Objective To develop an international reference range for plasma estradiol in postmenopausal women, support accurate assessment of concentrations during systemic and local (eg, vaginal) estradiol therapy, and improve risk prediction for diseases, including osteoporosis, breast, and endometrial cancers. Methodology Estradiol concentrations were measured using primarily liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays in 5 international cohorts of community-dwelling, postmenopausal women of primarily European ancestry aged 38-100 years who were not using exogenous estrogens (n = 7206). Measurements were harmonized to the Centers for Disease Control and Prevention (CDC) reference measurement procedure (RMP) by re-assaying a subset of samples for each cohort and generating recalibration equations. Reference intervals were determined for all women, non-obese women, and specific BMI categories. Results Estradiol concentrations from separate LC-MS/MS assays correlated closely with the CDC RMP, and harmonization minimized inter-assay variability. Estradiol concentrations correlated with BMI but not with chronological age. The reference range (2.5th-97.5th percentile) was 1.1-18.2 pg/mL (4.0-66.8 pmol/L) with median of 4.9 pg/mL (18.0 pmol/L) for all postmenopausal women and 1.1-12.5 pg/mL (4.0-45.9 pmol/L) with median of 4.1 pg/mL (15.1 pmol/L) for non-obese women (BMI &lt; 30). Reference ranges increased progressively with higher BMI categories. Conclusion Cross-calibration of estradiol measurements with the CDC RP enabled the development of harmonized plasma estradiol reference ranges for postmenopausal women who were not using exogenous estrogens, suitable for future studies to establish clinical utility. Increasing obesity in postmenopausal women was associated with increasing estradiol concentration and BMI category-specific reference ranges.